Genix Pharmaceuticals Corp (GENX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 10/31
(Values in thousands)
| 10-2024 | 10-2023 | 10-2022 | 10-2021 | 10-2020 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 1 | 547 | 564 | 537 | 362 |
| Accounts receivable | -4 | 15 | -12 | 3 | -4 |
| Accounts payable and accrued liabilities | 35 | 29 | 176 | -94 | 75 |
| Other Working Capital | 30 | 56 | -6 | -124 | 65 |
| Other Operating Activity | -249 | -869 | -942 | -751 | -693 |
| Operating Cash Flow | $-187 | $-221 | $-220 | $-428 | $-195 |
| Cash Flows From Investing Activities | |||||
| Net Acquisitions | N/A | N/A | N/A | N/A | -8 |
| Purchase Sale Intangibles | N/A | 0 | -3 | N/A | N/A |
| Investing Cash Flow | $N/A | $0 | $-3 | $N/A | $-8 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 187 | 282 | 169 | N/A | -5 |
| Debt Repayment | N/A | 0 | -21 | -14 | N/A |
| Common Stock Issued | N/A | N/A | N/A | N/A | 1,006 |
| Other Financing Activity | 0 | -59 | -55 | -115 | -133 |
| Financing Cash Flow | $187 | $223 | $93 | $-129 | $868 |
| Beginning Cash Position | 12 | 9 | 139 | 697 | 31 |
| End Cash Position | 11 | 12 | 9 | 139 | 697 |
| Net Cash Flow | $0 | $2 | $-130 | $-558 | $665 |
| Free Cash Flow | |||||
| Operating Cash Flow | -187 | -221 | -220 | -428 | -195 |
| Capital Expenditure | N/A | N/A | -3 | N/A | N/A |
| Free Cash Flow | -187 | -221 | -223 | -428 | -195 |